R&D channel feed

My­ovant read­ies NDA #3 as re­l­u­golix sails to its 5th pos­i­tive PhI­II — this time in en­dometrio­sis

5 years ago
FDA+

Sev­en years af­ter li­cens­ing BTK in­hibitor from Bio­gen, be­lea­guered pen­ny­s­tock biotech part­ner con­cedes de­feat

5 years ago

Sanofi wants to earn the rep for be­ing the hare in drug R&D. But that darn tor­toise keeps stick­ing its head out

5 years ago

Evoke Phar­ma fi­nal­ly lands ap­proval for lead and on­ly drug

5 years ago
FDA+

Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

5 years ago

Mer­ck ad­vances along a broad PhI­II front, aimed at carv­ing up Pfiz­er’s top-sell­ing vac­cine fran­chise. Could an am­bush lay in wait?

5 years ago

Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

5 years ago
Financing

Ab­b­Vie sweeps out ex­per­i­men­tal gas­tro drugs in a post-merg­er pipeline cleanup. And they can like­ly be yours for the right price

5 years ago
Deals

'A turn­ing point for the field': 4 years af­ter Seres fail­ure, Finch posts pos­i­tive mi­cro­bio­me da­ta

5 years ago

One of Roche’s spot­light PhI­II can­cer drug hope­fuls stum­bles in a key tri­al, with hit-and-miss re­sults

5 years ago

As Bio­Marin’s lead ri­val wanes, Pfiz­er and Sang­amo post a promis­ing up­date for he­mo­phil­ia A gene ther­a­py

5 years ago
Cell/Gene Tx

Tecen­triq pass­es neoad­ju­vant breast can­cer tri­al as Roche looks for ear­ly start on the next big check­point op­por­tu­ni­ty

5 years ago

Bio­Marin spells out a trou­bling slide in Fac­tor VI­II lev­els for its big block­buster con­tender val­rox

5 years ago
Cell/Gene Tx

Am­i­cus shares surge as Sanofi strug­gles to raise a cheer for mixed piv­otal da­ta for a PhI­II con­tender — and an­a­lysts blow a rasp­ber­ry

5 years ago

Adding bil­lions in val­ue, Eli Lil­ly suc­ceeds where Pfiz­er failed, halt­ing breast can­cer re­cur­rence

5 years ago

Take­da spins out a pipeline of ‘in­ter­est­ing but still dif­fi­cult’ psych drugs in $2B deal as it wraps up a post-merg­er R&D shake­out

5 years ago
Deals

A fail­ure at Eli Lil­ly, the come­back drug teplizum­ab shows off more up­beat di­a­betes da­ta in the run-up to an FDA fil­ing

5 years ago

Jazz Phar­ma’s $1B bet pays off with ac­cel­er­at­ed lung can­cer ap­proval

5 years ago
FDA+

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

5 years ago
Bioregnum
Opinion

With Sanofi en­ter­ing the mul­ti­ple myelo­ma mar­ket, J&J flash­es da­ta on new rare dis­ease

5 years ago

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a wrench­ing change­up

5 years ago
People

Eli Lil­ly launch­es PhI­II JAK study, aim­ing for the first drug to low­er mor­tal­i­ty in Covid-19

5 years ago
Coronavirus

Mo­men­ta clears a PhII hur­dle on nipo — but one big ri­val re­mains well in the lead in this packed field

5 years ago

Sure, Bit Bio got some sig­nif­i­cant cash for its cell cod­ing work. But it’s the in­sid­ers who are back­ing them that will gar­ner the at­ten­tion

5 years ago
Financing
First page Previous page 197198199200201202203 Next page Last page
A service from the Financial Times